Vol.

No.

March 05, 2021Mar 05, 2021

DOWNLOAD THE PDF

Cover Story

Not for sale: Fox Chase Cancer Center

Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market.

Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation”

By Paul Goldberg

NASEM: Reduce cancer drug waste by reformulating development, payments, dosing

By Alexandria Carolan

Cancer History Project Free

A 25-year retrospective: How NCCN changed the way cancer medicine is practiced—and paid for

By Paul Goldberg

Free In the Archives

Women’s History Month: Amy Reed, Carol Fabian

In Brief

Hans Clevers receives 2021 Pezcoller Foundation-AACR award

Sarah Hawley named associate director education, training programs at UMich Rogel Cancer Center

Lilli Petruzzelli named SVP of early clinical development at Genentech’s gRED

Brian Faith named VP of communications at City of Hope

Six early-career cancer researchers receive nearly $3 million total from The Parker Institute for Cancer Immunotherapy

Case Comprehensive Cancer Center receives $2.75 million to increase prostate cancer screening in African American men

Yale establishes Chênevert Family Brain Tumor Center

Funding Opportunities

DoD prostate cancer research funding opportunity for FY21

DoD kidney cancer research opportunity for FY21

Clinical Roundup

NCCN guidelines for histiocytosis clarify best practices for recently-defined cancers

Yale researchers identify T cells active against advanced melanoma

UNC Lineberger study: Engineered safety switch curbs severe side effects of CAR T immunotherapy

City of Hope researchers investigate checkpoint inhibitor combination for TNBC

GO2 Foundation initiates study to improve participation of Black communities in lung cancer clinical trials

Drugs & Targets

FDA approves lorlatinib for metastatic ALK-positive NSCLC

FDA authorizes first robotically-assisted surgical device for performing transvaginal hysterectomy

FDA grants accelerated approval to Pepaxto for relapsed or refractory multiple myeloma

CHMP recommends approval of Sarclisa + carfilzomib, dexamethasone for relapsed multiple myeloma

CHMP tissues positive opinion for Opdivo + Cabometyx as first-line treatment for advanced RCC

CHMP recommends approval of dostarlimab for women with recurrent or advanced endometrial cancer

Novartis completes in-licensing of tislelizumab

NCI Trials

NCI Trials for March 2021

The National Cancer Institute approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 35 - September 25, 2026